Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High – Should You Buy?

Trevi Therapeutics, Inc. (NASDAQ:TRVI)’s stock price hit a new 52-week high on Monday . The company traded as high as $18.47 and last traded at $18.3310, with a volume of 97753 shares trading hands. The stock had previously closed at $18.15.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TRVI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. JonesTrading reduced their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, March 19th. Wall Street Zen raised shares of Trevi Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Stifel Nicolaus set a $30.00 target price on shares of Trevi Therapeutics in a research report on Friday, May 8th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $20.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Trevi Therapeutics currently has an average rating of “Buy” and a consensus price target of $22.90.

Trevi Therapeutics Stock Performance

The firm has a market capitalization of $2.58 billion, a P/E ratio of -56.59 and a beta of 1.04. The stock has a 50-day moving average of $14.73 and a 200 day moving average of $12.77.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, equities analysts predict that Trevi Therapeutics, Inc. will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TRVI. Russell Investments Group Ltd. grew its holdings in Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after acquiring an additional 2,996 shares during the last quarter. KBC Group NV bought a new position in shares of Trevi Therapeutics in the first quarter worth about $29,000. Hilton Head Capital Partners LLC bought a new position in shares of Trevi Therapeutics in the fourth quarter worth about $40,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Trevi Therapeutics during the fourth quarter worth approximately $50,000. Finally, Strs Ohio acquired a new position in shares of Trevi Therapeutics during the first quarter worth approximately $52,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.